BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-06-03 13:00 |
BerGenBio presents new Phase II clinical data that bemcentinib in combination w…
|
English | 9.0 KB | ||
| 2019-06-02 13:00 |
BerGenBio presents new preliminary clinical and biomarker data showing durable …
|
English | 7.1 KB | ||
| 2019-05-31 12:07 |
BerGenBio ASA: Invitation to ASCO Update Call
|
English | 3.1 KB | ||
| 2019-05-15 21:00 |
BerGenBio to present new NSCLC and AML clinical data and biomarker data from Ph…
|
English | 6.8 KB | ||
| 2019-05-08 10:15 |
BerGenBio completes recruitment into second stage of Phase II trial with select…
|
English | 7.2 KB | ||
| 2019-05-08 05:02 |
BerGenBio ASA: Results for the First Quarter 2019
|
English | 1.7 MB | ||
| 2019-05-08 05:02 |
BerGenBio ASA: Results for the First Quarter 2019
|
English | 42.2 KB | ||
| 2019-05-08 05:02 |
BerGenBio ASA: Results for the First Quarter 2019
|
English | 8.1 KB | ||
| 2019-04-24 09:30 |
BerGenBio ASA: Invitation to First Quarter Presentation and Webcast
|
English | 3.2 KB | ||
| 2019-04-23 05:00 |
BerGenBio to present NSCLC and AML clinical data from Phase II development prog…
|
English | 4.4 KB | ||
| 2019-04-23 04:55 |
BerGenBio ASA: Share options to primary insiders
|
English | 1.7 KB | ||
| 2019-04-15 11:53 |
BerGenBio ASA: Share capital increase
|
English | 1.3 KB | ||
| 2019-04-12 05:00 |
BerGenBio ASA: Exercise of share options and increase of share capital
|
English | 2.1 KB | ||
| 2019-04-11 15:40 |
BerGenBio ASA (BGBIO): Primary Insider notification
|
English | 1.0 KB | ||
| 2019-04-09 05:00 |
BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference
|
English | 3.3 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
